| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.1M | — | +13.9% |
| SG&A Expense | $2.1M | — | +38.2% |
| Operating Income | -$4.2M | — | -20.2% |
| Net Income | -$4.3M | — | +36.6% |
| EPS (Basic) | $2.65 | — | +495.5% |
| EPS (Diluted) | $2.65 | — | +495.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.9M | -46.8% | -56.8% |
| Current Assets | $4.2M | -45.0% | -55.4% |
| Total Assets | $4.4M | -44.4% | -54.7% |
| Current Liabilities | $5.0M | +4.2% | +155.1% |
| Total Liabilities | $5.2M | +3.9% | +121.2% |
| Stockholders' Equity | -$851K |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.0M | — | -37.7% |
| Capital Expenditures | $9K | — | +0.0% |
| Investing Cash Flow | -$9K | — | +0.0% |
| Financing Cash Flow | $591K | — | -90.8% |
| Free Cash Flow | -$4.1M | — | -37.6% |
| -111.7% |